Bharat Immuno Peer Comparison

BSE: 524663

₹15.34

₹0.03 (0.20%)

As on 04-Sep-2026IST

Market cap

₹66 Cr

Revenue (TTM)

₹45 Cr

P/E Ratio

--

P/B Ratio

--

Div. Yield

0 %

Edit

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Market cap (₹ Cr)	66	2,734	285	206	42
Revenue (₹ Cr)	45	2,901	138	85	55
Net Profit (₹ Cr)	-16.64	16.16	-9.39	12.82	-2.86
Net Margin (%)	-36.43	0.55	-6.66	6.38	-5.15
RoE (%)	--	0.29	-9.20	20.84	-16.06
Price to Earnings	--	169.20	--	16.08	--
Price-To-Book	--	0.41	3.02	6.43	0.46

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Operating Revenue	44.61	2,412.92	93.07	189.07	52.23
Total Income	45.67	2,440.69	96.47	197.52	52.27
Total Expenditure	60.68	2,080.72	76.23	208.11	30.39
EBITDA	-16.07	332.20	16.84	-19.04	21.84
Depreciation	0.20	280.72	14.15	16.84	9.27
EBIT	-16.27	51.48	2.69	-35.88	12.57
Interest	7.06	85.69	11.87	7.45	7.99
Other Income	1.06	27.77	3.40	8.45	0.04
Exceptional Items	--	-48.15	-7.39	-10.39	--
Profit before Tax	-22.27	-54.59	-13.17	-45.27	4.62
Provision for Tax	-5.63	-24.79	-0.02	1.68	1.97
Profit after Tax	-16.64	-29.80	-13.15	-46.95	2.65

Liabilities (₹ Cr)

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Shareholder's Funds	88.21	5,809.67	45.44	108.60	51.87
Minority Interest	--	--	0.23	--	--
Non-Current Liabilities	-20.26	1,831.43	73.25	12.19	46.19
Current Liabilities	94.04	1,798.39	32.60	100.90	24.97
Total Liabilities	188.65	9,439.49	151.52	224.38	123.03

Assets (₹ Cr)

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Non-Current Assets	126.19	7,521.13	107.32	131.50	90.77
Current Assets	35.80	1,918.36	44.20	90.19	31.79
Total Assets	188.65	9,439.49	151.52	224.38	123.03
Total Debt*	70.22	1,824.51	72.18	33.26	62.40
Net Current Assets	-58.24	119.97	11.61	-10.71	6.82
Contingent Liabilities	0.04	442.92	33.99	63.73	--

Cashflow (₹ Cr)

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Cash From Operating Activities	10.89	265.95	8.95	20.02	14.83
Cash Flow from Investing Activities	0.46	-494.08	7.35	-2.13	-4.00
Cash from Financing Activities	-14.71	249.68	-21.64	-35.72	-11.18
Net Cash Inflow / Outflow	-3.36	21.55	-5.34	-17.83	-0.34

Ratios

Profitability Ratios

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
ROCE (%)	-25.63	0.43	-1.00	-19.83	11.06
ROE (%)	0.00	-0.52	-63.63	-33.82	5.44
ROA (%)	-9.41	-0.33	-7.80	-6.51	2.16
EBIT Margin (%)	-33.64	14.92	21.75	-5.60	41.88
Net Margin (%)	-36.43	-1.22	-13.63	-23.77	5.07
Cash Profit Margin (%)	-36.85	10.40	1.07	-15.93	22.81

Growth Ratios

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Revenue Growth (%)	-43.09	12.72	-52.05	-71.03	1.63
EBIT Growth (%)	-287.70	-3.95	-80.40	-139.36	35.11
Net Profit Growth (%)	-90.08	-265.46	-134.21	43.33	20.33
EPS Growth (%)	-90.08	-265.46	-131.67	87.18	15.16
Book Value Growth (%)	-260.28	4.70	109.94	-37.28	11.69

Valuation Ratios

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Price / Earnings	0.00	0.00	0.00	0.00	10.86
Price / Book Value	-4.16	0.34	11.47	1.85	0.56
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-10.48	9.97	18.86	-20.74	4.10
Market Cap (₹ Cr)	95.82	1,955.19	321.32	197.54	28.76

Solvency Ratios

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Debt to Equity	-3.05	0.31	2.58	0.31	1.21
Short term debt to equity ratio	0.80	0.12	0.17	0.19	0.22
Current Ratio	0.38	1.07	1.36	0.89	1.27
Quick Ratio	0.37	0.62	1.21	0.89	0.95
Interest Coverage	-2.15	0.36	-0.11	-5.07	1.58

Operating Efficiency Ratios

	Bharat Immuno	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Debtors to sales (%)	31.11	24.45	21.62	15.89	23.70
Asset Turnover	0.25	0.27	0.55	0.26	0.43
Receivable days	61.40	80.42	75.65	107.67	85.27
Inventory Days	154.12	109.59	29.71	1.38	62.14
Payable days	8.90	145.87	104.00	--	87.84
Cash Conversion Cycle	206.63	44.14	1.36	--	59.58

Annual
Quarterly